Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival

Journal of Experimental Medicine

Volumn 191, Issue 7, 2000, Pages 1209-1219

  Hohlbaum, Andreas M ^a   Moe, Signa ^a   Marshak Rothstein, Ann ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Chemotaxis; Fas ligand; Lymphoma; Neutrophil

Indexed keywords

FAS LIGAND; ISOPROTEIN; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; INFLAMMATION; LYMPHOMA CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BINDING SITES; CELL MEMBRANE; CELL SURVIVAL; FAS LIGAND PROTEIN; FEMALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED CBA; MICE, INBRED DBA; MICE, INBRED MRL LPR; NEUTROPHILS; PERITONEUM; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0034600068     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.7.1209     Document Type: Article

References (55)

1. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas hgand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
2. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
3. Lynch, D.H., M.L. Watson, M.R. Alderson, P.R. Baum, R.E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C.A. Smith, K. Hunter, et al. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:131-136.
4. Kägi, D. F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxictty. Science. 265:528-530.
5. Ju, ST., H. Cui, D.J. Panka, R. Ettinger, and A. Marshak-Rothstein. 1994. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 91:4185-4189.
6. Stalder, T., S. Hahn, and P. Erb. 1994. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 152:1127-1133.
7. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 373:444-448.
8. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
9. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
10. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
11. Griffith, T.S., X. Yu, J.M. Herndon, D.R. Green, and T.A. Ferguson. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 5:7-16.
12. Hellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630-632.
13. Stuart, P.M., T.S. Griffith, N. Usui, J. Pepose, X. Yu, and T.A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for conical allograft survival. J. Clin. Invest. 99: 396-402.
14. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, O. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1363-1366.
15. O'Connell, J., G.C. O'Sullivan, J.R. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
16. Strand, S., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366.
17. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57: 1007-1012.
18. Saas, P., P.R. Walker, M. Hahne, A.L. Quiquerez, V. Schnuriger, G. Perrin, L. French, E.G. Van Meir, N. de Tribolet, J. Tschopp, and P.Y. Dietrich. 1997. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Invest. 99:1173-1178.
19. Bennett, M.W. J. O'Connell, G.C. O'Sullivan, C. Brady, D. Roche, J.K. Collins, and F. Shanahan. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160:5669-5675.
20. Lau, H.T., M. Yu, A. Fontana, and C.J. Stoeckert, Jr. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:109-112.
21. Arai, H., S.Y. Chan, D.K. Bishop, and G.J. Nabel. 1997. Inhibition of the alloantibody response by CD95 ligand. Nat. Med. 3:843-848.
22. Allison, J., H.M. Georgiou, A. Strasser, and D.L. Vaux. 1997. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA. 94: 3943-3947.
23. Kang, S.M., D.B. Schneider, Z. Lin, D. Hanahan, D.A. Dichek, P.G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-743.
24. Kang, S.M., A. Hoffmann, D. Le, M.L. Springer, P.G., Stock, and H.M. Blau. 1997. Immune response and myoblasts that express Fas ligand. Science. 278:1322-1324.
25. Arai, H., D. Gordon, E.G. Nabel, and G.J. Nabel. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA. 94:13862-13867.
26. Seino, R., N. Kayagaki, R. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-170.
27. Miwa, R., M. Asano, R. Horai, Y. Iwakura, S. Nagata, and T. Suda. 1998. Caspase 1-independent IL-1beta release and inflammation induced by the apoptosis inducer Fas ligand. Nat. Med. 4:1287-1292.
28. Shimizu, M., A. Fontana, Y. Takeda, H. Yagita, T. Yoshimoto, and A. Matsuzawa. 1999. Induction of antitumor immunity with Fas/APO-1 ligaad (CD95L)-transfected neuroblastoma neuro-2.1 cells. J. Immunol. 162:7350-7357.
29. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligaad. J. Exp. Med. 182:1777-1783.
30. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO (Eur. Mol. Biol. Organ.) J. 14: 1129-1135.
31. Mariani, S.M., B. Matiba, C. Baumler, and P.H. Krammer. 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:2303-2307.
32. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, et al. 1996. Fas ligand in human serum. Nat. Med. 2:317-322.
33. Pietravalle, F., S. Lecoanet-Henchoz, H. Ulascy, J.P. Aubry, G. Elson, M.D. Edgerton, J.Y. Bonnefoy, and J.F. Gauchat, 1996. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J. Biol. Chem. 271: 5965-5967.
34. Sherry, U., and A. Cerami. 1988. Cachectin/tumor necrosis factor exerts endocrine, paracrine, and autocrine control of inflammatory responses. J. Cell Biol. 107:1269-1277.
35. Bazzoni, F., and B. Beutler. 1996. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1717-1725.
36. Perez, C., I. Albert, K. DeFay, N. Zachariades, L. Gooding, and M. Kriegler. 1990. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 63:251-258.
37. Tanaka, M., T. Itai, M. Adachi, and S. Nagata. 1998. Downregulation of Fas ligand by shedding. Nat. Med. 4:31-36.
38. Suda, T., M. Tanaka, K. Miwa, and S. Nagata. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J. Immunol. 157:3918-3924.
39. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045-2050.
40. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
41. Seino, K., K. Iwabuchi, N. Kayagaki, K. Miyata, I. Nagaoka, A. Matsuzawa, K. Fukao, H. Yagita, and K. Okumura. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161:4484-4488.
42. Ottonello, L., G. Tortolina, M. Amelotti, and F. Dallegri. 1999. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162:3601-3606.
43. Kayagaki, N., N. Yamaguchi, F. Nagao, S. Matsuo, H. Maeda, K. Okumura, and H. Yagita. 1997. Polymorphism of murine Fas ligand that affects the biological activity. Proc. Natl. Acad. Sci. USA. 94:3914-3919.
44. Walsh, C.M., A.A. Glass, V. Chiu, and W.R. Clark. 1994. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153:2506-2514.
45. cg, that complements the gld gene in induction of lymphadenopathy in the mouse. J. Exp. Med. 171:519-531.
46. Watanabe-Fukunaga, R., C. Brannan, N. Copeland, N. Jenkins, and S. Nagata. 1992. Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:314-317.
47. Graft, D., S. Muller, U. Korthauer, C. van Kooten, C. Weise, and R.A. Kroczek. 1995. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25:1749-1754.
48. Pietravalle, F., S. Lecoanet-Henchoz, J.P. Aubry, G. Elson, J.Y. Bonnefoy, and J.F. Gauchat. 1996. Cleavage of membrane-bound CD40 ligand is not required for inducing B cell proliferation and differentiation. Eur. J. Immunol. 26:725-728.
49. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J.L. Bodiner, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. AchaOrbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
50. Chen, J.J., Y. Sun, and G.J. Nabel. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science. 282: 1714-1717.
51. Takeuchi, T., T. Ueki, H. Nishimatsu, T. Kajiwara, T. Ishida, K. Jishage, O. Ueda, H. Suzuki, B. Li, N. Moriyama, et al. 1999. Accelerated rejection of Fas ligand-expressing heart grafts. J. Immunol. 162:518-522.
52. Gao, Y., J.M. Herndon, H. Zhang, T.S. Griffith, and T.A. Ferguson. 1998. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J. Exp. Med. 188:887-896.
53. Smith, J.A. 1994. Neutrophils, host defense, and inflammation: a double-edged sword. J. Leukoc. Biol. 56:672-686.
54. Zhang, H.G., X. Su, D. Liu, W. Liu, P. Yang, Z. Wang, C.K. Edwards, H. Bluethmann, J.D. Mountz, and T. Zhou. 1999. Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells. J. Immunol. 162:1423-1430.
55. Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat. Med. 5:930-937.